Document Detail


Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
MedLine Citation:
PMID:  16845254     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Fibrates were reported to be effective in reducing recurrent coronary events in coronary heart disease patients with elevated triglycerides. It is not known whether this effect is related to the extent of triglyceride reduction.
METHODS: Participants comprised 3090 coronary heart disease patients enrolled in the Bezafibrate Infarction Prevention study, which showed a nonsignificant reduction (9.4%; P=0.26) in fatal or nonfatal myocardial infarction and sudden death during a mean follow-up time of 6.2 years.
RESULTS: Significant reduction in triglyceride serum level was evident only among patients allocated to bezafibrate, ranging between 0.06 mmol/l (5 mg/dl) in the lowest decile of baseline triglycerides level and 0.68 mmol/l (60 mg/dl) in the highest baseline decile. The extent of triglyceride reduction with bezafibrate was significantly associated with the reduction of risk; relative risk reduction of 55% (hazards ratio: 0.45; 95% confidence interval: 0.24-0.84) was observed among patients with baseline triglycerides>or=2.26 mmol/l who reduced triglyceride level to >0.50 mmol/l (>44.3 mg/dl). In contrast, the risk of recurrent events among patients treated with bezafibrate and achieving less triglyceride reduction or failing to reduce triglyceride level was not significantly different from that of patients treated with placebo.
CONCLUSION: Bezafibrate treatment was associated with significant risk reduction among coronary heart disease patients with elevated triglyceride levels that substantially reduced their triglyceride level with treatment.
Authors:
Moti Haim; Michal Benderly; Valentina Boyko; Ilan Goldenberg; David Tanne; Alex Battler; Uri Goldbourt; Solomon Behar;
Related Documents :
10865834 - Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma.
6504864 - Prognostic importance of cholesterol levels after myocardial infarction.
11143764 - Triglycerides and coronary heart disease: implications of recent clinical trials.
15731554 - When to measure lipid profile after stroke?
11041104 - Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart...
6607464 - Rehabilitation of the mi survivor. management options to maximize posthospital outcome.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Coronary artery disease     Volume:  17     ISSN:  0954-6928     ISO Abbreviation:  Coron. Artery Dis.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-17     Completed Date:  2006-11-28     Revised Date:  2013-02-07    
Medline Journal Info:
Nlm Unique ID:  9011445     Medline TA:  Coron Artery Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  455-61     Citation Subset:  IM    
Affiliation:
Cardiology Department, Rabin Medical Center, Petach-Tikva, Sackler School of Medicine, Tel-Aviv University, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Bezafibrate / pharmacology*,  therapeutic use
Clofibric Acid / pharmacology*,  therapeutic use
Female
Humans
Hypertriglyceridemia / drug therapy*
Hypolipidemic Agents / pharmacology*,  therapeutic use
Male
Middle Aged
Prospective Studies
Recurrence / prevention & control*
Risk Assessment
Risk Factors
Triglycerides / blood*
Chemical
Reg. No./Substance:
0/Hypolipidemic Agents; 0/Triglycerides; 41859-67-0/Bezafibrate; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemodynamic responses and long-term follow-up results in patients using chronic beta 1-selective and...
Next Document:  Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarc...